Sierra Oncology Inc
NASDAQ:SRRA
Sierra Oncology Inc
Pre-Tax Income
Sierra Oncology Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sierra Oncology Inc
NASDAQ:SRRA
|
Pre-Tax Income
-$102.8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Zymeworks Inc
NYSE:ZYME
|
Pre-Tax Income
-$119.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Pre-Tax Income
-$103.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Pre-Tax Income
-$94.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Pre-Tax Income
-$61.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-19%
|
|
Spectral Medical Inc
TSX:EDT
|
Pre-Tax Income
-CA$17.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-4%
|
See Also
What is Sierra Oncology Inc's Pre-Tax Income?
Pre-Tax Income
-102.8m
USD
Based on the financial report for Mar 31, 2022, Sierra Oncology Inc's Pre-Tax Income amounts to -102.8m USD.
What is Sierra Oncology Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-16%
Over the last year, the Pre-Tax Income growth was -49%. The average annual Pre-Tax Income growth rates for Sierra Oncology Inc have been -23% over the past three years , -16% over the past five years .